Complete Filing Data
Annovis Bio, Inc. reported Stockholders Equity of $16.85 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Annovis Bio, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$28.9M | -$24.6M | -$56.2M | -$25.3M | -$14.5M | -$5.5M | -$991.0K |
| Research And Development Expense | $25.2M | $20.0M | $38.8M | $16.5M | $8.5M | $3.1M | $776.3K |
| Operating Income Loss | -$29.7M | -$26.7M | -$45.0M | -$25.5M | -$14.5M | -$6.6M | -$1.6M |
| Operating Expenses | $29.7M | $26.7M | $45.0M | $25.5M | $14.5M | $6.6M | $1.6M |
| Nonoperating Income Expense | $841.1K | $2.1M | -$11.2M | $182.7K | $50.1K | $1.2M | $614.6K |
| General And Administrative Expense | $4.5M | $6.7M | $6.2M | $9.0M | $6.1M | $3.6M | $829.4K |
| Interest Income Expense Nonoperating Net | $667.9K | $182.7K | $13.3K | $47.2K | -$40.9K | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$56.2M | -$25.3M | -$14.5M | -$5.5M | -$991.0K | ||
| Income Tax Expense Benefit |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$7.3M | -$6.2M | -$5.5M | -$12.6M | -$5.0M | -$1.1M | -$14.7M | -$9.5M | -$9.7M | -$6.4M | -$5.9M | -$5.2M | -$2.8M | -$2.5M | -$3.2M | -$1.0M | -$2.3M | -$441.6K | -$254.1K | -$344.7K | -$190.9K |
| Research And Development Expense | $6.3M | $5.2M | $5.0M | $2.7M | $5.8M | $6.5M | $13.8M | $8.3M | $7.8M | $4.1M | $4.0M | $2.1M | $1.4M | $1.8M | $2.4M | $718.9K | $856.5K | $66.4K | $2.0K | $6.0K | $6.0K |
| Operating Income Loss | -$7.4M | -$6.3M | -$6.3M | -$4.4M | -$7.8M | -$7.8M | -$14.9M | -$9.8M | -$10.0M | -$6.5M | -$6.0M | -$5.3M | -$2.9M | -$2.5M | -$3.2M | -$1.6M | -$2.5M | -$583.2K | -$241.8K | -$306.1K | -$186.8K |
| Operating Expenses | $7.4M | $6.3M | $6.3M | $4.4M | $7.8M | $7.8M | $14.9M | $9.8M | $10.0M | $6.5M | $6.0M | $5.3M | $2.9M | $2.5M | $3.2M | $1.6M | $2.5M | $583.2K | $241.8K | $306.1K | $186.8K |
| Nonoperating Income Expense | $172.3K | $51.4K | $745.6K | -$8.3M | $2.7M | $6.7M | $146.7K | $222.6K | $232.5K | $52.9K | $36.0K | $19.6K | $5.6K | $9.5K | $29.5K | $597.4K | $234.1K | $141.6K | -$12.3K | -$38.6K | -$4.1K |
| General And Administrative Expense | $1.1M | $1.1M | $1.3M | $1.7M | $2.0M | $1.3M | $1.0M | $1.5M | $2.2M | $2.4M | $1.9M | $3.1M | $1.5M | $709.6K | $839.6K | $884.9K | $1.7M | $516.7K | $239.8K | $300.0K | $180.8K |
| Interest Income Expense Nonoperating Net | $26.0K | $44.2K | $146.7K | $222.6K | $232.5K | $52.9K | $36.0K | $19.6K | $5.6K | $2.1K | $197.00 | $10.5K | $25.9K | $10.6K | -$12.3K | -$12.1K | -$4.1K | ||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$12.6M | -$5.0M | -$1.1M | -$14.7M | -$9.5M | -$9.7M | -$6.4M | -$5.9M | -$5.2M | -$2.8M | -$2.5M | -$3.2M | -$1.0M | -$2.3M | -$441.6K | -$254.1K | -$344.7K | -$190.9K | |||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $16.9M | $9.3M | -$7.8M | $28.3M | $44.5M | $7.5M | -$8.6M | -$7.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M | $1.9K | $35.3K |
| Retained Earnings Accumulated Deficit | -$163.7M | -$134.8M | -$110.3M | -$54.1M | -$28.7M | -$14.2M | -$8.8M | |
| Prepaid Expense Security Deposits And Other Assets Current | $1.5M | $3.4M | $4.5M | $7.6M | $315.5K | $44.7K | $10.6K | |
| Liabilities Current | $3.6M | $3.9M | $4.3M | $7.7M | $1.5M | $578.4K | $2.0M | |
| Liabilities And Stockholders Equity | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M | $8.1M | $1.1M | |
| Liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $1.5M | $578.4K | $2.6M | |
| Common Stock Value | $2.7K | $1.4K | $1.1K | $816.00 | $810.00 | $689.00 | $28.00 | |
| Cash And Cash Equivalents At Carrying Value | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M | $1.9K | |
| Assets | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M | $8.1M | $1.1M | |
| Accrued Liabilities And Interest And Employee Related Liabilities Current | $1.0M | $1.6M | $3.0M | $3.7M | $818.4K | $236.5K | $776.9K | |
| Accounts Payable Current | $2.6M | $2.3M | $1.3M | $4.0M | $688.1K | $341.9K | $1.2M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $9.0M | $4.8M | -$22.6M | -$17.3M | $37.6M | $8.1M | -$33.5K | |
| Assets Current | $36.0M | $46.0M | $8.1M | $747.5K | ||||
| Gain Loss On Changes In Fair Value Of Warrant Liability | $142.0K | $3.6M | -$11.8M | |||||
| Warrant Liability Noncurrent | $595.0K | $737.0K | $13.7M | |||||
| Amortization Of Debt Discount Premium | $396.00 | $3.7K | ||||||
| Derivative Liabilities Noncurrent | $106.0K | |||||||
| Increase Decrease Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities | $291.0K | |||||||
| Conversion Of Redeemable Convertible Preferred Stock To Common Stock | $7.1M | |||||||
| Conversion Of Convertible Promissory Notes Including Embedded Derivative To Common Stock | $672.5K | |||||||
| Non Cash Transaction Value Of Consideration Warrant Exercises | $9.3M | $606.2K | ||||||
| Grants Receivable Current | $735.1K | |||||||
| Equity Distribution Agreement Value Of Stock Issued During Period Net Of Issuance Costs | $6.6M | $156.8K | ||||||
| Deferred Offering Costs Noncurrent | $369.6K | |||||||
| Debt Instrument Unamortized Discount | $22.8K | |||||||
| Cash Paid For Financing Costs During Period | $50.0K | |||||||
| Stock Issued During Period Value Conversion Of Convertible Securities Preferred Stock | $7.1M | |||||||
| Deferred Finance Costs Noncurrent Net | $7.4K | |||||||
| Liabilities Noncurrent | $605.8K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $13.2M | $18.3M | $24.1M | $7.1M | -$1.8M | -$3.4M | $6.7M | $20.7M | $20.1M | $34.6M | $38.7M | $42.7M | $46.5M | $48.6M | $4.4M | $9.1M | $9.5M | $10.7M | -$8.4M | -$8.1M | -$7.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $15.3M | $17.1M | $22.2M | $12.6M | $4.0M | $3.1M | $6.4M | $15.7M | $16.8M | $32.0M | $36.0M | $42.7M | $47.5M | $49.2M | $5.6M | $8.8M | $9.8M | $11.1M | $56.3K | $104.6K | $336.6K | |
| Retained Earnings Accumulated Deficit | -$153.9M | -$146.6M | -$140.4M | -$129.0M | -$116.3M | -$111.3M | -$88.0M | -$73.3M | -$63.8M | -$46.3M | -$39.9M | -$34.0M | -$22.8M | -$20.0M | -$17.4M | -$12.5M | -$11.5M | -$9.2M | ||||
| Prepaid Expense Security Deposits And Other Assets Current | $1.9M | $4.3M | $4.5M | $1.7M | $1.0M | $4.7M | $3.9M | $7.1M | $8.8M | $5.1M | $4.0M | $1.4M | $195.2K | $272.0K | $362.1K | $136.4K | $238.7K | $283.0K | ||||
| Liabilities Current | $3.7M | $2.8M | $2.5M | $5.4M | $4.1M | $4.9M | $3.6M | $2.1M | $5.4M | $2.5M | $1.3M | $1.4M | $1.1M | $884.1K | $1.6M | $281.1K | $702.9K | $749.3K | ||||
| Liabilities And Stockholders Equity | $17.2M | $21.5M | $26.7M | $14.4M | $5.0M | $7.8M | $10.2M | $22.8M | $25.5M | $37.1M | $40.0M | $44.1M | $47.7M | $49.5M | $6.0M | $9.4M | $10.2M | $11.4M | ||||
| Liabilities | $4.0M | $3.1M | $2.7M | $7.3M | $6.8M | $11.2M | $3.6M | $2.1M | $5.4M | $2.5M | $1.3M | $1.4M | $1.1M | $884.1K | $1.6M | $281.1K | $702.9K | $749.3K | ||||
| Common Stock Value | $2.0K | $1.9K | $1.9K | $1.3K | $1.2K | $1.1K | $902.00 | $902.00 | $822.00 | $816.00 | $816.00 | $816.00 | $810.00 | $809.00 | $695.00 | $687.00 | $687.00 | $685.00 | ||||
| Cash And Cash Equivalents At Carrying Value | $15.3M | $17.1M | $22.2M | $12.6M | $4.0M | $3.1M | $6.4M | $15.7M | $16.8M | $32.0M | $36.0M | $42.7M | $47.5M | $49.2M | $5.6M | $8.8M | $9.8M | $11.1M | ||||
| Assets | $17.2M | $21.5M | $26.7M | $14.4M | $5.0M | $7.8M | $10.2M | $22.8M | $25.5M | $37.1M | $40.0M | $44.1M | $47.7M | $49.5M | $6.0M | $9.4M | $10.2M | $11.4M | ||||
| Accrued Liabilities And Interest And Employee Related Liabilities Current | $1.6M | $1.8M | $1.1M | $1.3M | $662.7K | $763.2K | $1.6M | $901.0K | $1.3M | $680.8K | $397.5K | $468.1K | $830.9K | $769.2K | $772.1K | $141.3K | $578.5K | $694.8K | ||||
| Accounts Payable Current | $2.1M | $974.3K | $1.4M | $4.1M | $3.4M | $4.1M | $1.9M | $1.2M | $4.2M | $1.8M | $901.8K | $929.0K | $289.7K | $114.8K | $824.6K | $139.8K | $124.4K | $54.5K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $11.7M | -$2.6M | -$11.6M | -$3.0M | -$2.5M | $11.1M | $301.3K | |||||||||||||||
| Assets Current | $7.8M | $10.2M | $10.2M | $22.8M | $25.5M | $37.1M | $40.0M | $44.1M | $47.7M | $49.5M | $6.0M | $9.4M | $10.2M | $11.4M | ||||||||
| Gain Loss On Changes In Fair Value Of Warrant Liability | $20.0K | -$140.0K | $558.0K | -$7.9M | $4.1M | $6.7M | ||||||||||||||||
| Warrant Liability Noncurrent | $299.0K | $319.0K | $179.0K | $1.5M | $2.2M | |||||||||||||||||
| Amortization Of Debt Discount Premium | $396.00 | $365.00 | ||||||||||||||||||||
| Derivative Liabilities Noncurrent | $442.5K | $505.0K | $6.3M | $13.7M | ||||||||||||||||||
| Increase Decrease Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities | $50.0K | $31.0K | ||||||||||||||||||||
| Conversion Of Redeemable Convertible Preferred Stock To Common Stock | $7.1M | |||||||||||||||||||||
| Conversion Of Convertible Promissory Notes Including Embedded Derivative To Common Stock | $672.5K | |||||||||||||||||||||
| Non Cash Transaction Value Of Consideration Warrant Exercises | ||||||||||||||||||||||
| Grants Receivable Current | $425.0K | $199.2K | $37.8K | |||||||||||||||||||
| Equity Distribution Agreement Value Of Stock Issued During Period Net Of Issuance Costs | $1.6M | $502.9K | ||||||||||||||||||||
| Deferred Offering Costs Noncurrent | $0.00 | $0.00 | $0.00 | |||||||||||||||||||
| Debt Instrument Unamortized Discount | $22.8K | |||||||||||||||||||||
| Cash Paid For Financing Costs During Period | ||||||||||||||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities Preferred Stock | $7.1M | |||||||||||||||||||||
| Deferred Finance Costs Noncurrent Net | $7.4K | |||||||||||||||||||||
| Liabilities Noncurrent |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $1.8M | $3.8M | $4.6M | $9.2M | $4.7M | $1.7M | $8.5K |
| Share Based Compensation | $1.8M | $3.8M | $4.6M | $9.2M | $4.7M | $1.9M | $8.5K |
| Net Cash Provided By Used In Operating Activities | -$25.6M | -$21.9M | -$40.0M | -$17.3M | -$9.1M | -$4.0M | -$476.5K |
| Net Cash Provided By Used In Financing Activities | $34.6M | $26.7M | $17.3M | $4.6K | $46.7M | $12.0M | $443.1K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.8M | -$1.1M | -$3.2M | $7.3M | $270.8K | $34.1K | -$5.1K |
| Increase Decrease In Accrued Liabilities | -$530.2K | -$1.4M | -$751.0K | $2.9M | $581.9K | -$406.0K | $182.4K |
| Increase Decrease In Accounts Payable | $284.5K | $1.0M | -$2.7M | $3.3M | $346.2K | -$695.7K | $969.1K |
| Proceeds From Stock Options Exercised | $2.0K | $0.00 | $8.4K | $4.6K | $95.1K | $9.2K | |
| Proceeds From Issuance Of Common Stock | $18.7M | $16.9M | $46.6M | $12.0M | |||
| Proceeds From Issuance Of Warrants | $8.0M | $450.0K | |||||
| Increase Decrease In Grants Receivable | -$735.1K | $735.1K | |||||
| Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs | |||||||
| Proceeds From Convertible Debt | $530.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $444.6K | $496.6K | $499.9K | $393.1K | $1.6M | $364.8K | $632.2K | $1.6M | $1.5M | $2.4M | $1.9M | $3.4M | $785.9K | $8.0K | $24.0K | $607.1K | $1.1M | $8.9K | |||
| Share Based Compensation | $499.9K | $364.8K | $1.5M | $1.9M | $3.4M | $8.0K | $24.0K | $629.0K | $1.1M | $0.00 | $0.00 | $0.00 | $8.9K | ||||||||
| Net Cash Provided By Used In Operating Activities | -$8.1M | -$7.0M | -$11.6M | -$3.0M | -$2.5M | -$970.4K | -$228.7K | ||||||||||||||
| Net Cash Provided By Used In Financing Activities | $19.8M | $4.4M | $7.4K | $4.6K | $3.0K | $12.1M | $530.0K | ||||||||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.1M | $222.8K | $1.1M | $1.1M | $317.5K | $272.4K | $48.0K | ||||||||||||||
| Increase Decrease In Accrued Liabilities | -$440.8K | -$2.2M | -$2.5M | -$350.3K | $535.6K | $2.2K | $58.9K | ||||||||||||||
| Increase Decrease In Accounts Payable | -$935.8K | $2.8M | $191.7K | $240.9K | $482.7K | -$983.0K | -$58.0K | ||||||||||||||
| Proceeds From Stock Options Exercised | $7.4K | $4.6K | $3.0K | $4.6K | |||||||||||||||||
| Proceeds From Issuance Of Common Stock | $3.9M | $12.1M | |||||||||||||||||||
| Proceeds From Issuance Of Warrants | $540.0K | ||||||||||||||||||||
| Increase Decrease In Grants Receivable | -$697.3K | ||||||||||||||||||||
| Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs | $19.8M | $3.9M | |||||||||||||||||||
| Proceeds From Convertible Debt | $530.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.40 | -$2.31 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | -$3.51 |
| Common Stock Shares Authorized | 70.0M | 70.0M | 70.0M | 70.0M | 35.0M | 10.2M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Diluted Shares Outstanding | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M | |
| Preferred Stock Shares Authorized | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 0.00 |
| Weighted Average Number Of Shares Outstanding Basic | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Earnings Per Share Basic | $-1.40 | $-2.02 | $-6.23 | $-3.10 | $-1.90 | $-0.87 | |
| Common Stock Shares Outstanding | 27.2M | 14.1M | 10.5M | 8.2M | 6.9M | 282.6K | |
| Common Stock Shares Issued | 27.2M | 14.1M | 10.5M | 8.2M | 6.9M | 282.6K | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Weighted Average Number Of Share Outstanding Basic And Diluted | 6.3M | 282.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.37 | -$0.32 | -$0.32 | -$0.97 | -$0.44 | -$0.72 | -$1.63 | -$1.07 | -$1.07 | -$0.79 | -$0.73 | -$0.64 | -$0.35 | -$0.34 | -$0.46 | -$0.15 | -$0.34 | -$0.10 | -$0.90 | -$1.22 | -$0.68 | ||
| Common Stock Shares Authorized | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 35.0M | 35.0M | 35.0M | 35.0M | 35.0M | 35.0M | 35.0M | 35.0M | 35.0M | 35.0M | 35.0M | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Weighted Average Number Of Diluted Shares Outstanding | 19.7M | 19.5M | 17.4M | 13.0M | 11.3M | 10.8M | 9.0M | 9.0M | 9.0M | 8.2M | 8.2M | 8.2M | 8.1M | 7.4M | 7.4M | 6.9M | |||||||
| Preferred Stock Shares Authorized | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | |||||
| Weighted Average Number Of Shares Outstanding Basic | 19.7M | 19.5M | 17.4M | 13.0M | 11.3M | 10.6M | 9.0M | 9.0M | 8.2M | 8.2M | 8.2M | 8.2M | 8.1M | 7.4M | 6.9M | 6.9M | |||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Earnings Per Share Basic | $-0.37 | $-0.32 | $-0.32 | $-0.97 | $-0.44 | $-0.10 | $-1.63 | $-1.07 | $-1.19 | $-0.79 | $-0.73 | $-0.64 | $-0.35 | $-0.34 | $-0.46 | $-0.15 | |||||||
| Common Stock Shares Outstanding | 20.2M | 19.5M | 19.5M | 13.3M | 11.7M | 11.0M | 9.0M | 9.0M | 8.2M | 8.2M | 8.2M | 8.2M | 8.1M | 8.1M | 8.1M | 6.9M | 6.9M | 6.9M | 6.8M | ||||
| Common Stock Shares Issued | 20.2M | 19.5M | 19.5M | 13.3M | 11.7M | 11.0M | 9.0M | 9.0M | 8.2M | 8.2M | 8.2M | 8.2M | 8.1M | 8.1M | 8.1M | 6.9M | 6.9M | 6.9M | 6.8M | ||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 7.4M | 6.9M | 6.9M | 6.9M | 4.6M | 282.6K | 282.6K | 282.6K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $180.6M | $144.2M | $102.5M | $82.4M | $73.2M | $21.8M | $200.6K |
| Stock Issued During Period Value Stock Options Exercised | $2.0K | $8.4K | $4.6K | $95.1K | $9.2K | ||
| Stock Issued During Period Value New Issues | $14.4M | $46.6M | $12.0M | ||||
| Income From Grants | $36.8K | $1.2M | $735.1K | ||||
| Investment Income Interest | $699.1K | $331.8K | $667.9K | ||||
| Fair Value Adjustment Of Warrants | -$142.0K | -$3.6M | $11.8M | ||||
| Unrealized Gain Loss On Derivatives | -$26.5K | -$79.5K | |||||
| Stock Issued During Period Value Warrants Exercised | $17.3M | $1.1M | |||||
| Amortization Of Financing Costs | $129.00 | $1.2K | |||||
| Financing Costs From Issuance Of Shares | 1.9M | ||||||
| Stock Issued During Period Shares Stock Options Exercised | 14.3K | 300.0K | 59.9K | 70.1K | 159.8K | 48.4K | |
| Stock Issued During Period Value Conversion Of Convertible Securities Convertible Promissory Notes | $672.5K | ||||||
| Stock Issued During Period Value Issued For Services | $122.8K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $167.0M | $164.9M | $164.4M | $136.0M | $114.6M | $108.0M | $94.7M | $94.1M | $83.9M | $80.9M | $78.6M | $76.7M | $69.3M | $68.6M | $21.8M | $21.7M | $21.0M | $19.9M | ||
| Stock Issued During Period Value Stock Options Exercised | $1.0K | $7.4K | $4.6K | $92.1K | $3.0K | $4.6K | $4.6K | |||||||||||||
| Stock Issued During Period Value New Issues | $4.9M | $5.0M | $3.9M | $8.6M | $46.7M | $12.0M | ||||||||||||||
| Income From Grants | $7.4K | $29.3K | $586.9K | $208.3K | $157.4K | |||||||||||||||
| Investment Income Interest | $152.3K | $191.4K | $187.6K | $135.4K | $26.0K | $44.2K | $146.7K | |||||||||||||
| Fair Value Adjustment Of Warrants | -$558.0K | -$6.7M | ||||||||||||||||||
| Unrealized Gain Loss On Derivatives | -$26.5K | -$26.5K | ||||||||||||||||||
| Stock Issued During Period Value Warrants Exercised | $16.1M | $1.2M | ||||||||||||||||||
| Amortization Of Financing Costs | $129.00 | $112.00 | ||||||||||||||||||
| Financing Costs From Issuance Of Shares | 524.1K | 1.3M | ||||||||||||||||||
| Stock Issued During Period Shares Stock Options Exercised | ||||||||||||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities Convertible Promissory Notes | $672.5K | |||||||||||||||||||
| Stock Issued During Period Value Issued For Services | $22.0K |
Most recent annual filing with the SEC: March 13, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.